Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Alexion Pharmaceuticals Inc

+ Add to Watchlist


181.9216 USD 5.8816 3.34%

As of 14:53:57 ET on 03/27/2015.

Snapshot for Alexion Pharmaceuticals Inc (ALXN)

Open: 175.6200 Day's Range: 175.4350 - 183.0000 Volume: 1,055,297
Previous Close: 176.0400 52wk Range: 136.3700 - 203.3000 1-Yr Rtn: +20.67%

Stock Chart for ALXN

No chart data available.
  • ALXN:US 181.9500
  • 1D
  • 1M
  • 1Y
Interactive ALXN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ALXN

Current P/E Ratio (ttm) 53.4721
Estimated P/E(12/2015) 30.9342
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) 3.4121
Est. EPS (USD) (12/2015) 5.8980
Est. PEG Ratio 1.2368
Market Cap (M USD) 36,882.00
Shares Outstanding (M) 202.15
30 Day Average Volume 1,151,188
Price/Book (mrq) 10.9917
Price/Sale (ttm) 16.1716
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/24/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ALXN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ALXN

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The Company develops C5 complement inhibitors and Apogens which are two classes of potential therapeutic compounds designed to selectively target specific disease-causing segments of the immune system.

Leonard Bell "Lenny"CEO/Treasurer/Co-FounderDavid L HallalChief Operating Officer
Vikas SinhaExec VP/CFOSaqib IslamExec VP/Chief Strategy Ofcr/Portfolio Mgr
More Company Profile & Key Executives for ALXN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil